Precision Neuroscience is developing Layer 7, a brain-computer interface that places an ultra-thin, flexible electrode film on the brain's surface rather than inserting probes into brain tissue. Thinner than a human hair, the film contains 1,024 microscopic electrodes on a sheet roughly the size of a postage stamp and conforms to the cortex's folds and contours.

A neurosurgeon deploys the array through an opening in the skull, sometimes as narrow as 400 to 900 micrometres, slides it between the skull and brain surface, and confirms placement with imaging. The array can later be removed through the same opening. In preclinical work, Precision Neuroscience deployed more than 2,000 electrodes at a rate exceeding 1,000 per minute and recorded simultaneously from 4,096 electrodes using four tiled arrays in a single procedure.

Each electrode samples electrical activity from a small area of the cortex. Software removes noise and uses machine learning to map neural activity to intended actions such as cursor movement, typing, or speech. Selected electrodes can also deliver targeted electrical stimulation, which could enable artificial touch feedback or closed-loop therapeutic stimulation.

Layer 7-T, the company's currently FDA-cleared product, is a temporary, single-use, sterile array authorized for implantation periods under 30 days. The passive device has no onboard electronics, wireless radio, or battery and connects via ribbon cables to standard external recording equipment. Neurosurgeons use it for high-resolution functional mapping during brain-tumor and epilepsy surgeries to identify motor, language, and sensory areas at finer spatial scales than conventional cortical grids.

Precision Neuroscience is also developing a fully implantable, wireless, chronic BCI system for people with severe paralysis from spinal-cord injury, stroke, or ALS. The system is intended to digitize and wirelessly transmit neural signals, run personalized decoders, and enable thought-controlled typing, communication, environmental controls, and device operation. The chronic wireless package remains under development and has not been validated in a pivotal human study.

Precision Neuroscience is a vertically integrated medical-device company selling B2B to hospitals, neurosurgical centers, and research institutions. Its initial go-to-market centers on per-procedure sales of single-use, sterile Layer 7-T electrode arrays and associated surgical tools. For the planned permanent BCI, the model shifts to B2B2C: Precision supplies the system through hospitals and clinicians, while insurers or government programs fund the procedure for the patient.

Commercialization is structured in three stages. Stage one uses the FDA-cleared temporary array in existing neurosurgical workflows for mapping and monitoring, generating early revenue while building surgeon familiarity, procurement relationships, and clinical data. Stage two uses the January 2026 Medtronic partnership to integrate Layer 7 with Medtronic's StealthStation surgical-navigation platform. The integration could enable bundled sales, co-marketing, and access to Medtronic's installed hospital base without requiring Precision to build an independent global sales channel. Stage three, the permanent therapeutic BCI, would add implant hardware, implanted wireless electronics, AI decoding software, clinical programming, and ongoing maintenance and upgrade revenue.

Precision manufactures its products at a 22,000-square-foot MEMS fabrication facility in Addison, Texas, with ISO Class 5 cleanroom capacity and more than 50 specialized tools. In-house fabrication provides direct control over electrode geometry, product iteration, and quality, while reducing dependence on external foundries. Published research reported production yields above 90%. This approach carries higher fixed costs and capital intensity before procedure volumes reach scale. Early-phase contribution margins are likely negative because of fixed manufacturing costs, clinical support expenses, and low capacity utilization. Margins could improve if high-value disposable arrays and implant systems maintain good yields across a larger procedure base.

Each procedure generates roughly 2 GB of raw neural data per minute per 1,024-channel array. Data from additional hospital sites could broaden the range of cortical recordings used to improve mapping and decoding models, potentially increasing clinical utility and adoption. Precision created a chief AI and data officer role in April 2026, indicating that the company plans to develop neural-data infrastructure as a core capability and potential source of recurring, higher-margin software revenue alongside electrode sales.

The BCI market is organized around tradeoffs among signal quality, invasiveness, procedural scalability, and long-term safety. Precision Neuroscience occupies a middle position: its cortical-surface array avoids penetrating brain tissue while providing substantially denser coverage than endovascular systems or conventional grids.

Neuralink is Precision Neuroscience's strongest competitor in funding, consumer mindshare, and full-stack engineering. Its N1 system inserts flexible intracortical threads using a proprietary surgical robot, records from 1,024 electrodes with a 3,000-electrode version in development, and includes fully implanted wireless electronics and custom chips. Neuralink reported 21 implanted participants by January 2026 and has programs in robotic-arm control, speech restoration, and visual prostheses, backed by a $650M Series E in 2025. Intracortical placement gives Neuralink access to single-neuron signals that can enable higher-performance cursor control and speech decoding, but it requires more complex surgery and penetrates tissue, complicating removal or replacement.

Paradromics competes more narrowly in high-bandwidth speech restoration. Its Connexus system uses 421 penetrating microelectrodes with an implanted cranial interface. In September 2026, Paradromics announced that its first chronically implanted participant had used the device for real-time open-ended speech communication. The company cites hermetic packaging, familiar neurosurgical techniques, and preclinical recordings exceeding three years of stability.

Blackrock Neurotech is the clinical incumbent, with Utah Arrays implanted in humans since 2004 and the longest institutional history in the category. Its MoveAgain system holds FDA Breakthrough Device designation. Blackrock competes through accumulated human evidence and academic relationships rather than raw channel count.

Synchron uses an endovascular approach, deploying its Stentrode through the jugular vein into a cerebral blood vessel using existing catheter-lab infrastructure. The procedure takes roughly two hours, most participants leave the hospital the next day, and the system avoids cranial surgery. Synchron raised a $200M Series D in November 2025 and has demonstrated native thought-based control using Apple's BCI Human Interface Device protocol.

Synchron's procedural simplicity and consumer-ecosystem integration provide access and cost advantages, particularly outside major academic neurosurgery centers. However, endovascular placement limits electrode positioning to available venous anatomy and provides substantially lower spatial resolution than Precision Neuroscience's direct cortical contact. The competitive question is whether Synchron can establish the reference procedure for basic digital autonomy before Precision's chronic implant reaches market.

In the temporary mapping market, where Precision Neuroscience has its only current FDA clearance, its immediate competitors are established electrode vendors such as Ad-Tech Medical, CorTec, DIXI Medical, and NeuroOne. These companies sell grids and strips already used by epilepsy centers and neurosurgical procurement departments, typically at lower channel counts ranging from single digits to low hundreds.

Layer 7-T's 1,024 contacts represent electrode densities roughly 200 to 1,000 times those of standard cortical grids. Incumbents compete through lower acquisition costs, compatibility with existing amplifiers, established purchasing contracts, and adequate performance for procedures that do not require Layer 7's resolution. Precision Neuroscience must translate electrode density into measurable operating-room value, such as faster mapping, smaller access openings, or better functional preservation, to justify a premium-priced consumable.

Precision Neuroscience's TAM expansion runs from a cleared temporary electrode to a chronic therapeutic platform, then across indications, geographies, and adjacent data and software markets.

The largest expansion opportunity is the shift from the temporary Layer 7-T to a chronically implanted, wireless BCI system for severe paralysis. The initial target population of ALS, spinal-cord injury, and brainstem-stroke patients includes roughly 315,000 Americans, while more than 20 million people live with spinal-cord injury globally. The company's partnership with SCI Ventures, backed by organizations including the Christopher & Dana Reeve Foundation and the Shepherd Center, provides access to patient communities and disability-focused clinical expertise.

Precision Neuroscience's non-penetrating, removable design could broaden eligibility relative to intracortical systems among patients and physicians reluctant to commit to an irreversible implant. The $250M Series D is earmarked for advancing Layer 7 through further FDA review and building commercialization infrastructure for this transition.

The near-term commercial entry point is high-resolution functional mapping during brain-tumor and epilepsy surgeries, for which Layer 7-T already has FDA clearance. The Medtronic partnership to integrate Layer 7 with StealthStation surgical navigation could make the array part of routine neurosurgical workflows rather than a standalone research system, connecting it to an installed base already used by hospitals.

This pathway gives Precision Neuroscience access to established procedure volumes and reimbursement structures while building surgeon familiarity and procurement relationships. The modular design has recorded simultaneously from 4,096 electrodes using four tiled arrays, allowing the company to sell multiple arrays per procedure and expand from point mapping to wide-area cortical visualization.

Layer 7's bidirectional recording and stimulation capability creates a path from assistive devices to therapeutic neuromodulation. Longer-term indications could include epilepsy monitoring, stroke rehabilitation, movement disorders, sensory restoration, and closed-loop neurostimulation, though each would require indication-specific evidence and regulatory review.

Neural data collected across more than 100 procedures and 18 institutions could be used to develop patient-specific decoders, AI-assisted surgical mapping software, digital biomarkers, and research tools for pharmaceutical companies and academic laboratories. The Series D investor base, which includes Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, and Hitachi Ventures, could facilitate geographic expansion into Europe, the UK, Japan, South Korea, and the Middle East.

Signal performance ceiling: Surface electrodes may be safer than penetrating systems but provide less precise single-neuron control for demanding speech, dexterity, and multidimensional decoding tasks, requiring Precision Neuroscience to prove that high electrode density and adaptive AI can compensate for this physiological constraint before competitors such as Neuralink and Paradromics establish intracortical performance as the clinical standard.

Reimbursement uncertainty: No established reimbursement category exists for permanent implanted BCIs, and without hospital and physician payments that cover the device, surgery, rehabilitation, and lifelong clinical support, a technically successful chronic implant could struggle commercially even after regulatory approval.

Partner dependence: The Medtronic integration reduces the need for an independent hospital sales channel but concentrates distribution leverage with a single partner that could gain negotiating power over economics, customer ownership, and the product roadmap, or eventually acquire or internally develop alternative electrode technology.